CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Beigene Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Beigene Ltd
C/O Mourant Governance Services (Cayman)
94 Solaris Avenue, Camana Bay
Phone: (345) 949-4123p:345 949-4123 GRAND CAYMAN, BEJ  KY1-1108  Cayman Islands Ticker: 61606160
Business Summary
BeiGene, Ltd. is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. The Company has an oncology pipeline of more than 50 investigational assets. Its products include BRUKINSA, TEVIMBRA, XGEVA, BLINCYTO, KYPROLIS, POBEVCY, and others. BRUKINSA is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). TEVIMBRA is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is engaged in the sale of XGEVA, BLINCYTO and KYPROLIS in China under a license from Amgen and POBEVCY in China under a license from Bio-Thera. The Company’s pipeline products include Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, Xaluritamig, and others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Co-Founder, Executive Chairman of the Board, Chief Executive Officer John V.Oyler 57 10/1/2010 10/1/2010
President, Chief Operating Officer, General Manager, China XiaobinWu 63 4/1/2021 4/30/2018
Co-Founder, Non-Executive Director XiaodongWang 62 2/8/2016 2/8/2016
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
BeiGene (Beijing) Co., Ltd. No. 30 Science Park Road Beijing China

Business Names
Business Name
49B
6160
688235
63 additional Business Names available in full report.

General Information
Number of Employees: 11,000 (As of 3/31/2025)
Outstanding Shares: 1,538,382,893 (As of 5/21/2025)
Shareholders: 29,773
Stock Exchange: HKG
Federal Tax Id: 981209416


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, June 5, 2025